We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Oh doctor

30 June 2010 By Robert Cyran

Patrick SoonShiong has had runins with minority shareholders in the past yet made them rich too. The sale of his Abraxis for more than $2.9 billion looks another happy ending for SoonShiong, and his backers. Even at the rich price, buyer Celgene may end up benefiting.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)